Fill out the form below to learn more about Hologic’s breast biopsy and treatment products and have a sales rep contact you.
1 Compared to the MultiCare® Platinum System.
2 Preference survey results of 155 Eviva users – 2015.
3 Based on a survey of 165 patients post-procedure at 3 hospitals.
4 Compared to 2D.
5 Schrading S, Martine D, Dirrichs T, et al. “Digital Breast Tomosynthesis-guided Vacuum-assisted Breast biopsy: Initial Experiences and Comparison with Prone Stereotactic Vacuum-assisted Biopsy.” Radiology. 2015 274:3, 654-662 E-pub 2014 Nov 12.
6 Compared to standard approach.
7 Internal testing performed at Hologic and maintained in PLM, 2006, SecurMark, TriMark biopsy site markers.
8 FDA K042290.
9 Compared to Eviva device. 2017 data on file.
10 Internal testing performed at Hologic and maintained in PLM, 2007, Celero biopsy device.
11 Englander, B., 2013. An Evaluation of the Hologic® Celero® Vacuum Assisted Handheld Device for Ultrasound Guided Breast Biopsies, WP-00006 Rev.002 (09/13) US/International.
12 Kaplan, S. 2010. The Benefits of the Hologic Eviva Vacuum-Assisted Stereotactic Breast Biopsy Device, WP-00023 (4/11).
13 Data collected from 100 cases performed at various sites using the Sertera biopsy device.
14 2016 Kadence International survey of 200 healthcare professionals.
15 Based on Tumark® Data Collection Study, 3 clinicians at 3 hospitals for 71 marker placements, 2017.
16 Based on Tumark® Data Collection Study, 3 clinicians at 3 hospitals for 45 marker placements, 2017.
17 Shah C, Badiyan S, Ben Wilkinson J, Vicini F, Beitsch P, Keisch M, Arthur D, Lyden M. Treatment Efficacy with Accelerated Partial Breast Irradiation (APBI): Final Analysis of the American Society of Breast Surgeons MammoSite® Breast Brachytherapy Registry Trial. Ann Surg Oncol. 2013 Aug 22. [Epub ahead of print] PubMed PMID: 23975302.
18 King TA, Bolton JS, Kuske RR, et al. Long-term results of wide-field brachytherapy as the sole method of radiation therapy after segmental mastectomy for Tis1,2 breast cancer. Am J Surg. 2000; 180:299-304.
19 All clinical data used to support this 5-Day Targeted Therapy™ system claim was derived from use of the Mammosite® system.
20Internal testing performed at Hologic and maintained in PLM 2018, Eviva biopsy device.
21 Internal testing performed at Hologic and maintained in PLM 2016, Sertera biopsy device.